- Home
- ACLX
ACLX
Arcellx Inc.
as 06-20-2025 4:00pm EST
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | 163 | City: | REDWOOD CITY |
| Market Cap: | 3.5B | IPO Year: | 2022 |
| Target Price: | $111.42 | AVG Volume (30 days): | 631.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.86 - $107.37 | Next Earning Date: | 08-07-2025 |
| Revenue: | $76,809,000 | Revenue Growth: | -41.66% |
| Revenue Growth (this year): | -34.21% | Revenue Growth (next year): | 112.68% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | Jun 10 '25 | Sell | $67.36 | 1,500 | $101,040.00 | 0 | |
| Patel Kavita | ACLX | Director | May 20 '25 | Sell | $58.43 | 1,500 | $87,645.00 | 0 | |
| Patel Kavita | ACLX | Director | Apr 29 '25 | Sell | $64.20 | 1,500 | $96,300.00 | 0 | |
| Patel Kavita | ACLX | Director | Apr 8 '25 | Sell | $57.50 | 1,500 | $86,250.00 | 0 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
5 days ago
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
MT Newswires
5 days ago
Citigroup Initiates Arcellx at Buy With $110 Price Target
Business Wire
a month ago
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
Insider Monkey
a month ago
Baron Discovery Fund Initiated a Position in Arcellx (ACLX)
MT Newswires
a month ago
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise
Business Wire
a month ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Insider Monkey
a month ago
Here’s Why Arcellx (ACLX) Declined in Q1
Simply Wall St.
a month ago
Arcellx First Quarter 2025 Earnings: Misses Expectations
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.